• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对于大多数起始CD4细胞计数为350个细胞/立方毫米或更高的患者而言,在接受7年高效抗逆转录病毒治疗后,CD4细胞计数达到800个细胞/立方毫米或更高是可行的。

CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater.

作者信息

Gras Luuk, Kesselring Anouk M, Griffin James T, van Sighem Ard I, Fraser Christophe, Ghani Azra C, Miedema Frank, Reiss Peter, Lange Joep M A, de Wolf Frank

机构信息

HIV Monitoring Foundation, Amsterdam, The Netherlands.

出版信息

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):183-92. doi: 10.1097/QAI.0b013e31804d685b.

DOI:10.1097/QAI.0b013e31804d685b
PMID:17414934
Abstract

OBJECTIVE

CD4 cell count changes in therapy-naive patients were investigated during 7 years of highly active antiretroviral therapy (HAART) in an observational cohort.

METHODS

Three endpoints were studied: (1) time to >or=800 CD4 cells/mm in 5299 therapy-naive patients starting HAART, (2) CD4 cell count changes during 7 years of uninterrupted HAART in a subset of 544 patients, and (3) reaching a plateau in CD4 cell restoration after 5 years of HAART in 366 virologically suppressed patients.

RESULTS

Among patients with <50, 50 to 200, 200 to 350, 350 to 500, and >or=500 CD4 cells/mm at baseline, respectively, 20%, 26%, 46%, 73%, and 87% reached >or=800 CD4 cells/mm within 7 years of starting HAART. Periods with HIV RNA levels >500 copies/mL and age >or=50 years were associated with lesser increases in CD4 cell counts between 6 months and 7 years. Having reached >or=800 CD4 cells/mm at 5 years, age >or=50 years, and >or=1 HIV RNA measurement >1000 copies/mL between 5 and 7 years were associated with a plateau in CD4 cell restoration.

CONCLUSIONS

Restoration to CD4 cell counts >or=800 cells/mm is feasible within 7 years of HAART in most HIV-infected patients starting with >or=350 cells/mm and achieving sufficient suppression of viral replication. Particularly in patients >or=50 years of age, it may be beneficial to start earlier than current guidelines recommend.

摘要

目的

在一项观察性队列研究中,对初治患者在7年高效抗逆转录病毒治疗(HAART)期间的CD4细胞计数变化进行了调查。

方法

研究了三个终点:(1)5299例开始接受HAART的初治患者达到CD4细胞计数≥800个/mm³的时间;(2)544例患者亚组在7年不间断HAART期间的CD4细胞计数变化;(3)366例病毒学抑制患者在HAART 5年后CD4细胞恢复达到平台期的情况。

结果

基线时CD4细胞计数分别<50、50至200、200至350、350至500以及≥500个/mm³的患者中,分别有20%、26%、46%、73%和87%在开始HAART后7年内达到CD4细胞计数≥800个/mm³。HIV RNA水平>500拷贝/mL的时期以及年龄≥50岁与6个月至7年期间CD4细胞计数增加较少相关。在5年时达到CD4细胞计数≥800个/mm³、年龄≥50岁以及在5至7年期间≥1次HIV RNA测量>1000拷贝/mL与CD4细胞恢复达到平台期相关。

结论

对于大多数开始时CD4细胞计数≥350个/mm³且实现病毒复制充分抑制的HIV感染患者,在HAART 7年内将CD4细胞计数恢复至≥800个/mm³是可行的。特别是对于年龄≥50岁的患者,比当前指南建议更早开始治疗可能有益。

相似文献

1
CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater.对于大多数起始CD4细胞计数为350个细胞/立方毫米或更高的患者而言,在接受7年高效抗逆转录病毒治疗后,CD4细胞计数达到800个细胞/立方毫米或更高是可行的。
J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):183-92. doi: 10.1097/QAI.0b013e31804d685b.
2
Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.影响接受长期高效抗逆转录病毒治疗的HIV阳性患者CD4细胞计数增加的因素。
J Infect Dis. 2004 Nov 15;190(10):1860-8. doi: 10.1086/425075. Epub 2004 Oct 8.
3
Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.根据基线CD4+ T细胞计数,长期高效抗逆转录病毒疗法对CD4+ T细胞的反应。
J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):702-13. doi: 10.1097/00126334-200406010-00007.
4
CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.CD4+ T 细胞计数和超过 5 年高效抗逆转录病毒治疗后的血浆 HIV-1 RNA 水平。
J Acquir Immune Defic Syndr. 2011 Aug 15;57(5):421-8. doi: 10.1097/QAI.0b013e31821e9f21.
5
Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.停止抗逆转录病毒治疗的无症状HIV感染患者的长期随访
Clin Infect Dis. 2005 Aug 1;41(3):390-4. doi: 10.1086/431487. Epub 2005 Jun 22.
6
Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.开始接受高效抗逆转录病毒治疗(HAART)且CD4 + T细胞计数≥200个细胞/立方毫米的HIV-1阳性患者临床进展的预测因素。
Antivir Ther. 2007;12(6):941-7.
7
CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.在接受高效抗逆转录病毒治疗并实现持续病毒学抑制的患者中,治疗开始6年后的CD4 +细胞计数。
Clin Infect Dis. 2007 Feb 1;44(3):441-6. doi: 10.1086/510746. Epub 2006 Dec 20.
8
Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3.在CD4细胞计数低于50个/立方毫米时开始接受高效抗逆转录病毒治疗的患者的治疗结果变化。
J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):202-5. doi: 10.1097/QAI.0b013e31815b1291.
9
A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients.一个帮助确定 HIV 感染患者最佳时机和抗逆转录病毒策略的决策树。
Epidemiol Infect. 2011 Dec;139(12):1835-44. doi: 10.1017/S0950268810002980. Epub 2011 Jan 14.
10
Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.在一个加勒比发展中国家的非临床试验环境中,对高效抗逆转录病毒疗法的免疫和病毒学反应。
HIV Med. 2006 Mar;7(2):99-104. doi: 10.1111/j.1468-1293.2006.00347.x.

引用本文的文献

1
A comparative assessment of CD4 recovery in a cohort of patients on different HAART regimens in a Nigerian tertiary healthcare facility.在尼日利亚一家三级医疗机构中,对接受不同高效抗逆转录病毒治疗(HAART)方案的一组患者的CD4恢复情况进行比较评估。
Afr Health Sci. 2024 Jun;24(2):10-18. doi: 10.4314/ahs.v24i2.3.
2
Factors Influencing Immune Restoration in People Living with HIV/AIDS.影响艾滋病毒/艾滋病感染者免疫恢复的因素
J Clin Med. 2022 Mar 28;11(7):1887. doi: 10.3390/jcm11071887.
3
A Comparison of Postoperative Surgical Outcomes among Women Undergoing Obstetric Fistula Repair with and without HIV.
感染HIV与未感染HIV的女性接受产科瘘修补术后手术结果的比较。
Int J MCH AIDS. 2021;10(2):191-197. doi: 10.21106/ijma.509. Epub 2021 Oct 30.
4
Substance use and HIV stage at entry into care among people with HIV.艾滋病毒感染者开始接受治疗时的物质使用情况和艾滋病毒阶段
Arch Public Health. 2021 Aug 28;79(1):153. doi: 10.1186/s13690-021-00677-2.
5
Effect of Traditional Chinese Medicine Therapy on the Trend in CD4 T-Cell Counts among Patients with HIV/AIDS Treated with Antiretroviral Therapy: A Retrospective Cohort Study.中药疗法对接受抗逆转录病毒治疗的艾滋病毒/艾滋病患者CD4 T细胞计数变化趋势的影响:一项回顾性队列研究
Evid Based Complement Alternat Med. 2021 Jul 15;2021:5576612. doi: 10.1155/2021/5576612. eCollection 2021.
6
Pharmacogenetic Associations Between Atazanavir/ and Efavirenz/rs3745274 () Account for Specific Adverse Reactions in Chilean Patients Undergoing Antiretroviral Therapy.阿扎那韦与依非韦伦/rs3745274之间的药物遗传学关联解释了智利接受抗逆转录病毒治疗患者的特定不良反应。
Front Pharmacol. 2021 May 19;12:660965. doi: 10.3389/fphar.2021.660965. eCollection 2021.
7
Residual immune dysfunction under antiretroviral therapy.抗逆转录病毒治疗下的残留免疫功能障碍。
Semin Immunol. 2021 Jan;51:101471. doi: 10.1016/j.smim.2021.101471. Epub 2021 Mar 3.
8
The effect of "universal test and treat" program on HIV treatment outcomes and patient survival among a cohort of adults taking antiretroviral treatment (ART) in low income settings of Gurage zone, South Ethiopia.“普遍检测与治疗”项目对埃塞俄比亚南部古拉格地区低收入环境中接受抗逆转录病毒治疗(ART)的成年人群队列的艾滋病毒治疗结果和患者生存情况的影响。
AIDS Res Ther. 2020 May 18;17(1):19. doi: 10.1186/s12981-020-00274-3.
9
Long-term immunological responses to treatment among HIV-2 patients in Côte d'Ivoire.科特迪瓦 HIV-2 患者治疗的长期免疫反应。
BMC Infect Dis. 2020 Mar 12;20(1):213. doi: 10.1186/s12879-020-4927-x.
10
Socioeconomic disparity of immunologic outcome among people living with HIV in Guangxi, China.中国广西 HIV 感染者免疫结局的社会经济差异。
AIDS Care. 2021 Mar;33(3):347-351. doi: 10.1080/09540121.2020.1738004. Epub 2020 Mar 8.